IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Optimal Titration Regimen for SBR759 in Lowering Serum Phosphate Levels in Asian Chronic Kidney Disease Patients on Hemodialysis (SBR759)
This study has been completed.
Sponsor:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT00704678
First received: June 23, 2008
Last updated: September 22, 2016
Last verified: September 2016
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study will determine the titration regimen for SBR759 compared to sevelamer HCl in lowering serum phosphate levels in Asian Chronic Kidney Disease patients on hemodialysis
| Condition | Intervention | Phase |
|---|---|---|
| Chronic Kidney Disease | Drug: SBR759 Drug: Sevelamer HCl | Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A 12-week, Open Label, Multicenter, Titration Study, With a 12 Month Extension, to Determine the Optimal Titration Regimen for SBR759, Compared to Sevelamer HCl, in Lowering Serum Phosphate Levels in Asian Patients With Chronic Kidney Disease on Hemodialysis |
Resource links provided by NLM:
Further study details as provided by Novartis ( Novartis Pharmaceuticals ):
Primary Outcome Measures:
- Responder rates achieving target serum phosphate levels. [ Time Frame: Week 12 ]
Secondary Outcome Measures:
- Responder rates in target patients with serum calcium-phosphate levels. [ Time Frame: Week 12 ]
| Enrollment: | 203 |
| Study Start Date: | August 2008 |
| Primary Completion Date: | June 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
1g bid
|
Drug: SBR759
1g tid
|
|
Active Comparator: 2
0.8 g tid
|
Drug: Sevelamer HCl
0.8 g tid
|
|
Experimental: 3
1.5 g tid
|
Drug: Sevelamer HCl
1.5 g tid
|
|
Active Comparator: 4
1.6 g tid
|
Drug: Sevelamer HCl
1.6 g tid
|
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion criteria
- Men or women of at least 18 years old or 20 years old in Japan.
- Stable maintenance of hemodialysis 3 times per week.
- Controlled serum phosphate if under phosphate-binder therapy.
- Serum phosphate level > 6.0 mg/dL (> 1.9 mmol/L) prior to study treatment initiation.
Exclusion criteria
- Peritoneal dialysis or a non-conventional hemodialysis technique .
- Parathyroidectomy or transplant scheduled during the study.
- Uncontrolled hyperparathyroidism
- History of hemochromatosis or ferritin > 800 µg/L.
- Clinically significant GI disorder
- Unstable medical condition other than Chronic Kidney Disease.
- Treated with sevelamer HCl monotherapy or SBR759.
- Treated with oral iron.
- Other protocol-defined inclusion/exclusion criteria may apply.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00704678
Please refer to this study by its ClinicalTrials.gov identifier: NCT00704678
Locations
| Japan | |
| Novartis Investigative Site | |
| Koriyama, Fukushima, Japan | |
| Novartis Investigative Site | |
| Midori, Gunma, Japan | |
| Novartis Investigative Site | |
| Hitachiomiya, Ibaraki, Japan | |
| Novartis Investigative Site | |
| Moriya, Ibaraki, Japan | |
| Novartis Investigative Site | |
| Sashima-gun, Ibaraki, Japan | |
| Novartis Investigative Site | |
| Takamatsu, Kagawa, Japan | |
| Novartis Investigative Site | |
| Tsu, Mie, Japan | |
| Novartis Investigative Site | |
| Okayama City, Okayama, Japan | |
| Novartis Investigative Site | |
| Sakai, Osaka, Japan | |
| Novartis Investigative Site | |
| Kasukabe, Saitama, Japan | |
| Novartis Investigative Site | |
| Nagano, Japan | |
| Novartis Investigative Site | |
| Shizuoka, Japan | |
| Taiwan | |
| Novartis Investigative Site | |
| Changhua, Taiwan | |
| Novartis Investigative Site | |
| Kaoshiung, Taiwan | |
| Novartis Investigative Site | |
| Taipei, Taiwan | |
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
| Study Director: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Novartis Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT00704678 History of Changes |
| Other Study ID Numbers: |
CSBR759A2202 |
| Study First Received: | June 23, 2008 |
| Last Updated: | September 22, 2016 |
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
|
Chronic Kidney Disease hemodialysis hyperphosphatemia Asian patients |
Additional relevant MeSH terms:
|
Kidney Diseases Renal Insufficiency, Chronic Urologic Diseases Renal Insufficiency |
Sevelamer Chelating Agents Sequestering Agents Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on June 27, 2017